A Phase 2 interventional study of NDV01 intravesical controlled release formulation of gemcitabine and docetaxel in Non Muscle Invasive Bladder Cancer, sponsored by Relmada Therapeutics, Inc.. Recruiting at 1 site in Israel. Open to participants aged 18 Years to 80 Years. Per ClinicalTrials.gov, last updated 2026-09-02.
Sponsored by Relmada Therapeutics, Inc. · Phase 2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 20 studies testing gemcitabine in Non-Muscle Invasive Bladder Neoplasms — 11 open to participants now, 16 under way, 3 of them phase 3. Gemcitabine · Non-Muscle Invasive Bladder Neoplasms.
Among the 20 studies testing gemcitabine in Non-Muscle Invasive Bladder Neoplasms, this one is the 10th largest by planned enrollment, is one of 2 that started in 2024, is one of 10 in phase 2, reaches primary completion later than 6 of the 15 other live ones, and was the 13th registered.
294 studies on the registry are indexed under Non-Muscle Invasive Bladder Neoplasms; 126 are open to participants now.
Browse Non-Muscle Invasive Bladder Neoplasms studies →11 of the 20 studies testing gemcitabine in Non-Muscle Invasive Bladder Neoplasms are open now, in 12 countries. Recruiting first, the newest first:
Alliance for Clinical Trials in Oncology · Sites in United States
Ages 18+
Mayo Clinic · Sites in United States
Ages 18+
Ferring Pharmaceuticals · Sites in United States, Canada, Czechia and 5 more countries
Ages 18+
Ekaterina Laukhtina · Sites in Austria
Ages 18+
Al-Azhar University · Sites in Egypt
By country, each count listing its studies:
Gemcitabine: first FDA approval 1996 (GEMZAR). What it is approved for, and how studies give it, is on its page →
Of the 92 Non-Muscle Invasive Bladder Neoplasms studies recruiting now, 77 (84%) set no upper age limit and 5 (5%) stop at 75 or younger; 2 take children under 18; 2 take healthy volunteers.
This study: 18 Years to 80 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
20 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 4 · Phase 2 14 · Phase 3 3 · Phase 4 1
First in 2003; this study’s year is marked. 2 started in 2024.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 70 is above the median of 62 across 231 interventional studies indexed under Non-Muscle Invasive Bladder Neoplasms.
Median enrollment 70 across the 20 interventional studies. Of the 4 that completed or were terminated, 0 (0%) have results posted.
This tab as a report to print or save as PDF → With an account.
5 of 20 have an industry lead sponsor. The 10 most frequent:
Relmada Therapeutics, Inc. is the lead sponsor of 11 studies on the registry; 2 are open to participants now.
Relmada Therapeutics, Inc. has 3 studies filed under Non-Muscle Invasive Bladder Neoplasms — fewer than ten, so there is no comparison to draw.
6 of the studies testing gemcitabine in Non-Muscle Invasive Bladder Neoplasms that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06829823ImmunityBio, Inc.Clinical Trial of Ablation Therapy in Participants With Intermediate-Risk Non-Muscle Invasive Papillary Bladder Cancer | 2026-11 |
| NCT07064863Queen's UniversityA Tumor Immune Biomarker Guided Approach for Improving Response to BCG in Patients With High-risk NMIBC. | 2027-07-31 |
| NCT07189793First Affiliated Hospital of Wenzhou Medical UniversityToripalimab ± Sequential Intravesical Gemcitabine-Mitomycin C for BCG-Unresponsive/-Intolerant High-Risk NMIBC: Open-Label Randomized Phase 2 Study | 2027-10 |
| NCT06663137Relmada Therapeutics, Inc.A Study to Evaluate the Safety and Efficacy of NDV-01 in Participants With NMIBC | 2027-11 |
| NCT04179162Memorial Sloan Kettering Cancer CenterBacillus Calmette-Guérin (BCG) and Gemcitabine in People With High-Grade Non-Muscle Invasive Bladder Cancer That Came Back After BCG Treatment | 2027-11 |
Add all 6 to your calendar (.ics) → With an account.
Among the 20 studies testing gemcitabine in Non-Muscle Invasive Bladder Neoplasms, from their registry updates:
This tab as a report to print or save as PDF → With an account.
This is a prospective, single-arm study evaluating the safety and efficacy of NDV01 KIT, a fixed-dose combination of gemcitabine HCl and docetaxel, administered via intravesical instillation in patients with high-grade Non-Muscle Invasive Bladder Cancer (NMIBC). NDV01 KIT includes 60 mL Carbopol Gel followed by 15 g NDV01 solution (gemcitabine HCl 1000 mg and docetaxel 40 mg), administered biweekly for six treatments, followed by monthly maintenance therapy for up to 12 months. The study includes a pharmacokinetic (PK) sub-study assessing systemic exposure to NDV01's active ingredients.
Eligible patients who sign informed consent will receive intravesical treatment with NDV01 KIT, consisting of a sequential instillation of Carbopol Gel followed by NDV01 solution using a 14F urethral catheter. The treatment phase includes six instillations on Days 1, 14, 28, 42, 56, and 70. Primary Disease Evaluation (PDE) will be conducted on Day 100 (±3). Patients achieving a complete response may continue into a maintenance phase with monthly instillations through Month 12.
Maintenance period of monthly treatments on Day 107, Day 140, Day 187, Day 220, Day 250, Day 287, Day 310, and Day 340.
The Primary Disease Evaluation (PDE) will be performed on Study Day 100±3.
A subset of patients will participate in a PK sub-study involving up to 15 blood draws to assess systemic levels of gemcitabine and docetaxel during the first treatment cycle.
Primary Objectives:
Assess safety of NDV01 KIT through the study period. Evaluate the complete response (CR) rate in patients with high-grade NMIBC.
Secondary Objectives:
Assess the durability of CR. Evaluate event-free survival (defined as high-grade recurrence-free survival). Assess the durability of event-free survival. Determine incidence and time to cystectomy. Determine overall survival. Monitor response durability through long-term follow-up.
Exploratory Objective:
Evaluate pharmacokinetic parameters of NDV01 KIT in a subset of patients during the initial treatment phase.
A subject that fails to meet CR at PDE visit will undergo reinduction of 6 biweekly installations of NDV01, which will be followed by maintenance treatments per the protocol schedule.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Subjects may participate in the study if they meet all the following criteria:
Inclusion criteria:
Exclusion criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).
Your pathology report is the document that shows this.
The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.
Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Histologically or cytologically confirmed
The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).
Your pathology report is the document that shows this.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Life expectancy
The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ECOG performance status
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Childbearing potential
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Postmenopausal
Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Metastases
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Biopsy and archival tissue
A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.
Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cancer (malignancy)
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
1. Treatment phase: 6 biweekly instillations - six instillations on Days 1, 14, 28, 42, 56, and 70 2. Maintenance phase: monthly administration - maintenance period of monthly treatments on Day 107, Day 140, Day 187, Day 220, Day 250, Day 287, Day 310, and Day 340 A subject that fails to meet CR at PDE visit will undergo reinduction of 6 biweekly installations of NDV01, which will be followed by maintenance treatments per the protocol schedule.
Drug: NDV01 intravesical controlled release formulation of gemcitabine and docetaxel
Drug pages: Gemcitabine · Docetaxel
NDV01 is administered intravesically using a catheter.
Also known as: Gemcitabine and docetaxel
Number of Patients with Complete Response (CR) in High-Grade NMIBC
Complete response is defined by at least one of the following criteria: Negative cystoscopy and negative or atypical urine cytology; and/or Positive cystoscopy with biopsy-confirmed benign or low-grade NMIBC, along with negative urine cytology.
Time frame: 48 weeks
Frequency and severity of Adverse Events (AEs), including Serious Adverse Events (SAEs) and Treatment-emergent AEs (TEAEs) occurring at any time during the study Serious Adverse Events (SAEs) Treatment-Emergent Adverse Events (TEAEs)
Any new Change from Baseline to End of Study (EOS) in investigators assessment
Time frame: 48 weeks
Durability of Complete Response (CR) in High-Grade NMIBC
Evaluate how long patients maintain CR over time.
Time frame: 48 weeks
Number of Patients with CR Among Those with Carcinoma In Situ (CIS)
Includes those with or without co-existing high-grade Ta or T1 papillary disease.
Time frame: 48 weeks
Incidence of Event-Free Survival (EFS) at 12 Months
Event-free survival is defined as survival without recurrence of high-grade disease.
Time frame: 48 weeks
Durability of event-free survival in patients with high-grade Ta or T1 papillary disease (without concomitant CIS), who have no recurrence of high-grade Ta or T1 papillary disease
Tumor recurrence
Time frame: 48 weeks
Pharmacokinetic parameters of NDV01 KIT will be evaluated
PK measurement expressed as maximum plasma concentration for NDV01 and PK measurement expressed as half-life and area under curve for NDV01 Pharmacokinetic (PK).
Time frame: 20 weeks
Plan to share: No — Not yet
No publications or documents are linked to this record.
Started Aug 2024 (actual). Primary completion is estimated for Nov 2027, 39 months after the start.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drugs tested here: Gemcitabine · Docetaxel
Non-Muscle Invasive Bladder Neoplasms →
Relmada Therapeutics, Inc.